title: Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia.
abstract: Currently Alzheimer's disease and schizophrenia are both well-established neuropsychiatric diseases. Nonetheless, the treatment of these disorders is not unanimous and fully effective. As a consequence, several approaches have been studied to improve patient's conditions. In this context, the development of new drug nanodelivery systems to increase drug bioavailability and reduce adverse effects has been claimed as a good option. Among these systems we focus on the ones that seem to be most promising, such as lipidbased systems (e.g. liposomes, nanoemulsions and lipid nanoparticles), drug nanocrystals, polymeric nanoparticles and micelles. Moreover, the application of these systems by means of alternative administration routes is also discussed. Regardless of the satisfactory results and the associated progresses that have been done in the last years, more studies are required to quickly licence the application of drug nanodelivery systems in human medicines.
authors.forename: A C
authors.initials: AC
authors.lastname: Silva
authors.forename: E
authors.initials: E
authors.lastname: González-Mira
authors.forename: J M Sousa
authors.initials: JM
authors.lastname: Lobo
authors.affiliation: Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, P-4050-313 Porto Portugal. ana.silva@ff.up.pt.
authors.forename: M H
authors.initials: MH
authors.lastname: Amaral
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D018696:Neuroprotective Agents